Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederroche.com
Investor Update
Get the latest updates from Investor Update directly as they happen.
Follow now 330 followers
Latest posts
Last updated about 16 hours ago
FDA approves Roche’s Susvimo as the first and only continuous delivery treatment for the leading cause of diabetes-related blindness
about 16 hours ago
Susvimo is the first and only continuous delivery treatment that offers an...
Invitation to Roche’s Virtual Immunology/WCN Investor Event
2 days ago
We are pleased to invite investors and analysts to participate in our...
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2024 results with 7% sales growth; fourth quarter marks third straight quarter of 9% growth
6 days ago
Group sales grew by 7%1 at constant exchange rates (CER; 3% in...
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2024 results with 7% sales growth; fourth quarter marks third straight quarter of 9% growth
6 days ago
Basel, 30 January 2025 Group sales grew by 7%1 at constant exchange...
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2024 results with 7% sales growth; fourth quarter marks third straight quarter of 9% growth
6 days ago
Basel, 30 January 2025 Group sales grew by 7%1 at constant exchange...
Roche’s Itovebi demonstrated statistically significant and clinically meaningful overall survival benefit in a certain type of HR-positive advanced breast cancer
8 days ago
Updated overall survival (OS) results - a key secondary endpoint - reinforce...
Roche announces new results from EMBARK demonstrating significant sustained benefits of Elevidys in ambulatory individuals with Duchenne muscular dystrophy (DMD)
9 days ago
Across three key functional outcomes, North Star Ambulatory Assessment (NSAA), Time to...
Reminder: Invitation to Roche’s Full Year Results 2024 Presentation
13 days ago
Roche will publish its Full Year Results of 2024 prior to the...
Roche receives FDA clearance with CLIA waiver for cobas® liat molecular tests to diagnose sexually transmitted infections at the point of care
14 days ago
More than 1 million curable sexually transmitted infections (STIs) are acquired every...
Roche purchases shares in tender offer for Poseida Therapeutics, Inc.
28 days ago
Basel, 8 January 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced...
Invitation to Roche’s Full Year Results 2024 Presentation
about 1 month ago
Roche will publish its Full Year Results of 2024 prior to the...
Roche’s Phase IIb study of prasinezumab missed primary endpoint, but suggests possible benefit in early-stage Parkinson’s disease
about 2 months ago
PADOVA study showed numerical delay in motor progression and positive trends on...